Kaletra: Therapy With Double Protease Inhibitors

PMOS: Kaletra Double Protease Inhibitors

Therapy with lopinavir/ritonavir (Kaletra) and one other protease inhibitor in Human Immunodeficiency Virus participants

This study is intended to observe and collect data on the usage, dosing, tolerability, and effectiveness of lopinavir/ritonavir (Kaletra) when used as part of a Nucleoside Reverse Transcriptase Inhibitors-free double protease regimen. Enrollment in the study was independent of the decision to prescribe Kaletra.

Inclusion Criteria:

• Participants with Human Immunodeficiency Virus infection
• Participants on lopinavir/ritonavir (Kaletra) and one other protease inhibitor

Exclusion Criteria:

• Hypersensitivity against lopinavir, ritonavir or other ingredients
• Severe liver insufficiency
• No concomitant astemizole, terfenadine, oral midazolam, triazolam, cisapride, pimozide, amiodarone, ergotamine, dihydroergotamine, ergometrine, methylergometrine, vardenafil and St. John's wort